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Abstract Vanadium, a trace metal known to accu-
mulate in bone and to mimic insulin, has been shown
to regulate mammalian bone formation using in vitro
and in vivo systems. In the present work, short- and
long-term effects of metavanadate (containing mono-
meric, dimeric, tetrameric and pentameric vanadate
species) and decavanadate (containing decameric
vanadate species) solutions on the mineralization of
a fish bone-derived cell line (VSa13) were studied
and compared to that of insulin. After 2 h of
incubation with vanadate (10 μM in monomeric
vanadate), metavanadate exhibited higher accumula-
tion rates than decavanadate (6.85±0.40 versus 3.95±
0.10 μg V/g of protein, respectively) in fish VSa13
cells and was also shown to be less toxic when
applied for short periods. In longer treatments with
both metavanadate and decavanadate solutions, sim-
ilar effects were promoted: stimulation of cell
proliferation and strong impairment (75%) of extra-
cellular matrix (ECM) mineralization. The effect of
both vanadate solutions (5 μM in monomeric vana-
date), on ECM mineralization was increased in the
presence of insulin (10 nM). It is concluded that
chronic treatment with both vanadate solutions stimu-
lated fish VSa13 cells proliferation and prevented
ECM mineralization. Newly developed VSa13 fish
cells appeared to be appropriate in the characterization
of vanadate effects on vertebrate bone formation,
representing a good alternative to mammalian systems.
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Abbreviations
DMEM Dulbecco’s modified Eagle medium
ECM Extracellular matrix
ERK Extracellular signal-regulated kinase
FBS Fetal bovine serum
MAPK Mitogen-activated protein kinase
MTS (3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxy-methoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium
PBS Phosphate-buffered saline
PI3-K Phosphatidyl inositol-3 kinase
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Introduction
Vanadium, an essential trace element found in animals
and higher plants (Anke 2004) and described to be
accumulated in mammalian bone (Etcheverry et al.
1984), has been shown to display important biological
effects in association with its physicochemical prop-
erties, e.g. insulin-like activity and regulation of
phosphatases and ATPases activity (Nielsen and
Uthus 1990). Vanadium, which easily transitions
between three oxidation states, namely, V(III), V(IV)
and V(V), has been proposed to be potentially
important for its role as a biometal (Rehder 1999,
2003). Vanadate (V(V)), which is the most stable
oxidation state in aerobic conditions, forms in
solution monomeric vanadate species with different
states of protonation, such as HVO24 or H2VO

4 ,
depending on pH value. However, at physiological
pH values and at millimolar range of concentrations,
several n-meric species (n=1 to 10), normally
ascribed as vanadate oligomers, can occur simulta-
neously in equilibrium, such as monomeric (V1),
dimeric (V2) and tetrameric (V4) vanadate species
(Amado et al. 1993). Eventually, even decameric (V10)
vanadate species can be formed upon medium
acidification (Aureliano and Gândara 2005). These
vanadate oligomers species have been shown to
interact with several proteins, thus affecting many
biological systems (Crans et al. 2004). For instance,
monomeric vanadate as been described to behave as a
phosphate analogue, inhibiting (or, in some cases,
stimulating) several phosphatases (acid, alkaline and
protein phosphatases), phosphorylases, ribonucleases
and ATPases (Crans et al. 2004). Conversely, other
vanadate oligomers, such as the decameric vanadate,
has been described to inhibit non-competitively
several enzymes, among others, proteins involved in
muscle contraction and regulation such as myosin
ATPase and sarcoplasmic reticulum calcium ATPase,
thus contributing for the several biological processes
influenced by vanadate (Aureliano and Madeira 1994;
Tiago et al. 2004; Aureliano and Gândara 2005).
The most important clinical effect of vanadium is
probably its ability to mimic or to enhance the effect
of insulin, as demonstrated in various in vivo and in
vitro studies using streptozocin-treated diabetic rats
(Heyliger et al. 1985; Meyerovitch et al. 1987) and
adipocyte cultures (Dubyak and Kleinzeller 1980;
Shechter and Karlish 1980). Insulin, a peptide that
binds to specific membrane tyrosine kinase receptors,
initiates intracellular signalling that either results in
the regulation of protein, lipid, carbohydrate and
mineral metabolism, or cell differentiation and prolif-
eration, depending on the involved pathways: phos-
phatidyl inositol-3 kinase (PI3-K) pathway for
metabolic effects or mitogen-activated protein kinase
(MAPK) pathway for cell proliferation and differen-
tiation effects (Cheatham and Kahn 1995; Cohick and
Clemmons 1993; LeRoith 2000). Vanadium insulin-
mimetic properties have been associated to the
activity of tyrosine phosphatases and consequent
activation of tyrosine kinase receptors, including the
insulin receptor (Goldwaser et al. 2000; Shechter et al.
1995; Shisheva and Shechter 1993). In vertebrates, a
major process regulated by insulin (and insulin-like
growth factor 1) is linear bone growth (McCarthy et al.
2000; Moriyama et al. 2000). Vanadate was also
shown to exhibit strong metabolic and mitogenic
effects, as demonstrated by in vitro studies using
mammalian bone-derived cell lines (and also using rat
calvaria and chondrocyte primary cultures) (Canalis
1985a; Kato et al. 1987; Lau et al. 1988). These effects
have been extensively studied using two mammalian
cell lines, MC3T3-E1 and UMR106, and important
features, such as tyrosine phosphorylation and activa-
tion of signalling mechanisms, have been character-
ized (Barrio and Etcheverry 2006; Cortizo and
Etcheverry 1995; Salice et al. 1999). Although
repetitively studied in mammals, vanadate effects have
not been investigated in marine vertebrates (e.g. fish
and amphibians), despite being recognized as the
second most abundant transition metal in seawater
(Rehder 2003).
In this paper, we describe the effects of two
different vanadate solutions on the growth and
mineralization performances of a gilthead seabream
bone-derived cell line (VSa13) recently developed in
our laboratory (Pombinho et al. 2004) and capable of
mineralizing its extracellular matrix.
Materials and methods
Dulbecco’s modified Eagle medium (DMEM), fetal
bovine serum (FBS), antibiotics (penicillin and
streptomycin), antimycotic (fungizone), trypsin-
EDTA solution and L-glutamine were purchased from
Invitrogen. Tissue culture dishes were purchased from
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Sarstedt or Nunc. CellTiter 96 non-radioactive prolif-
eration assay kit was purchased from Promega. All
other reagents were purchased from Sigma-Aldrich
unless otherwise stated.
Cell culture maintenance
Cultured cells were maintained in DMEM supple-
mented with 1% penicillin-streptomycin, 1% fungi-
zone, 2 mM L-glutamine and 10% FBS, and
incubated at 33°C in a 10% CO2 humidified atmo-
sphere. Confluent cell cultures were divided (1:2)
every 3–4 days using trypsin–EDTA solution.
Vanadate solution preparation
Metavanadate stock solution (50 mM, pH 6.7) was
prepared from ammonium metavanadate (NH4VO3).
Decavanadate stock solution was obtained by adjust-
ing the pH of the former solution to 4.0, as described
elsewhere (Aureliano and Madeira 1994). The ac-
quired characteristic orange color in decavanadate
solution upon acidification reveals the presence of
decameric vanadate species (V10). Decavanadate
stock solution was always adjusted to pH 7.0
immediately before using it. Both vanadate solutions
were stored at 4°C. Although total vanadate concen-
tration does not change, note that in case of
decavanadate solutions the concentration in decameric
vanadate species was effectively reduced 10-fold,
meaning that stock decavanadate solutions contain
5 mM decameric vanadate species. However, vana-
date concentrations are always given for monomeric
vanadate, i.e. total vanadate.
Characterization of vanadate solutions
The composition of both vanadate solutions was
analysed by 51V Nuclear Magnetic Resonance (NMR)
spectroscopy, as described elsewhere (Aureliano and
Madeira 1994). Briefly, the composition of vanadate
solutions upon dilution into DMEM was analysed in a
Bruker AM-400 spectrometer at 105.2 MHz equipped
with a 5-mm multinuclear inverse probe, using a 90°
pulse Fourier transform technique. Spectra were
acquired at room temperature using 0.5 ml of vanadate
samples in the medium, containing at least 10% D2O,
under the following conditions: spectral width
45,455 Hz, accumulation time 0.05 s and relaxation
delay 0.01 s. 51V NMR chemical shifts are reported
relative to an external reference of VOCl3 (0 ppm). The
relative areas of the several free or/and bound vanadate
resonances were integrated and the line widths were
obtained after subtracting the value (20 Hz) used in
line broadening. The concentration of each vanadate
oligomer Vx was calculated from the fractions of the
total integrated areas observed in the recorded spectra
as described (Equation 1). The symbol A corresponds
to the area measured for the x vanadate species with
the n aggregation number (number of vanadium
atoms), At, the sum of measured areas and [Vt]
corresponds to total vanadate concentration.
Vx½  ¼ AxAt 
Vt½ 
n
ð1Þ
The calculated concentrations of vanadate oligomers
were reproducible within 2–4%. For quantitative meas-
urements, all spectra parameters were kept constant.
Vanadate concentrations are always given for mono-
meric vanadate, i.e. total vanadium.
Unlike metavanadate, decavanadate solutions are
unstable. The partial deoligomerization of decameric
vanadate species present at the decavanadate solutions
upon dilution in DMEM medium was analysed by
ultraviolet/visible spectroscopy at 400 nm, as de-
scribed elsewhere (Soares et al. 2006).
Cell viability measurement
Cytotoxic and proliferative effects of vanadate olig-
omers on VSa13 cells were assessed through cell
viability analysis using the CellTiter 96 non-radioactive
proliferation assay kit according to the manufacturer’s
instructions. Tetrazolium reagent (3-(4,5-dimethylthiazol-
2-yl)-5-(3-carboxy-methoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium; inner salt,MTS) and the electron-coupling
reagent, phenazine methosulfate, were mixed in solu-
tion in a 20:1 proportion. Once added to cell culture,
MTS is reduced into formazan by the dehydrogenase
enzyme found in metabolically active cells. Formazan
formation, which is proportional to the number of living
cells (Malich et al. 1997), was followed at 490 nm
in 96-well tissue culture dishes. Incubation with
20 μl of reagent mixture during 1 h was determined
to be the optimal conditions for VSa13 cell viability
measurement. Vanadate cytotoxic effects were studied
in confluent cell cultures (approximately 1.7×104 cells/
well) while effects on cell proliferation were investi-
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gated in low-density cell cultures (starting from
1.5×103 cells/well).
Vanadium accumulation measurement
Cells were cultured for 0, 1, 2, 4, 8 and 24 h in the
presence of 10 μM metavanadate or decavanadate. At
appropriate times, cell cultures were washed three
times with phosphate-buffered saline (PBS), supple-
mented with 1 ml of MilliQ water (Millipore) and
placed at −80°C for 10 h. Frozen cells were thawed at
room temperature for 15 min, collected using a cell
scraper and transferred into a 2-ml microcentrifuge
tube. Cell culture dishes were washed once with 1 ml
of MilliQ water and washing solution was transferred
into the microcentrifuge tube containing the initial
cell extract. Total protein content was quantified from
cell extracts using Bradford reagent. Samples were
then digested at 100°C with 30 μl of 65% HNO3 and
final solid residues dissolved in 5% HCl solution.
Vanadium concentration was determined by atomic
absorption spectrometry analysis using a GBC Avanta
atomic absorption spectrometer equipped with a GBC
GF 3000 graphite furnace system and a GBC PAL
3000 auto sampler working at a furnace program of
63 s with an argon gas flow of 3.0 L/min. The
vanadium lamp was operated at 318.2 nm, with slit
width of 0.2 nm, and the instrument was calibrated
against a series of solutions containing 12.5, 25, 37.5
and 50 ppb of vanadium. Calibrating standards were
obtained by successive dilutions of a standard
solution of vanadium 1002±2 mg/L (Merck). The
detection and quantification limits of the instrument
for these analysis conditions, determined according to
ISO 8466-1, were 5 and 11 ppb, respectively.
Extracellular matrix mineralization and nodule
detection
Cells were seeded in 24-well plates at 2×104 cells/well
and cultured in DMEM supplemented with 10% FBS.
To induce ECM mineralization, confluent cultures
received medium supplemented with 50 μg/mL of
L-ascorbic acid (vitamin C), 10mMβ -glycerophosphate
and 4 mM CaCl2 up to 4 weeks. Wherever appropriate,
cells were washed three times with PBS at 4°C, fixed
with 10% formaldehyde (in PBS) for 1 h at 4°C,
washed three times with distilled water, then incubated
with 5% silver nitrate for 30 min under ultraviolet
light. Relative levels of ECM mineralization were
determined by densitometric methods using Quantity 1
software (Bio-Rad).
Statistical analysis
The data were presented as average and standard
deviation of measurements taken at least in three
separate experiments. Statistical significance of data
was analysed wherever indicated by Student t test or
analysis of variance (ANOVA) analysis. Differences
were considered to be significant at P<0.05.
Results
Vanadate solutions characterization in DMEM
51V-NMR spectroscopy of 1 and 5 mM decavanadate
solutions in DMEM, at pH 7.0, revealed three signals
attributed to three specific vanadium atoms in V10
structure: V10A at −515 ppm, V10B at −498 ppm and
V10C at −425 ppm (Fig. 1a). Conversely, in 1 and
5 mM metavanadate solutions (Fig. 1a), detected
signals ascribed to mono- (V1), di- (V2), tetra- (V4)
and pentameric (V5) vanadate species, respectively,
at −556 ppm, −571 ppm, −579 ppm and at 587 ppm
(Fig. 1a). Monomeric NMR signal is clearly broad-
ened, with a half line-width value (270 Hz) approx.
3.4-fold of normal value (80 Hz), probably caused by
vanadate interactions with compounds present in
DMEM such as glucose (25 mM) and piruvate
(1 mM), or even interactions with several proteins
also present in the medium. For each metavanadate
concentration in DMEM (1 and 5 mM), different
amounts of mono (V1), di (V2), tetra (V4) and
pentameric (V5) species have been observed, that
corresponded to different species profiles (Fig. 1b).
While tetrameric species were predominant at 5 mM
metavanadate, monomeric vanadate was the major
specie in the lower concentration (Fig. 1b). Con-
versely, decameric vanadate species present in the
decavanadate solutions increased linearly with total
vanadate concentration (Fig. 1c).
Although 51V-NMR spectroscopy is an essential
technique for the analysis of vanadate oligomers
composition and interactions, approximately 1 h
acquisition time was necessary to obtain a clear
spectrum of 1 mM decavanadate solution (Fig. 1a).
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In this sense, 51V-NMR spectroscopy is not adequate to
follow the decomposition kinetics of decavanadate, in
particular for vanadate concentrations lower than 1 mM.
However, the disappearance of decameric vanadate
species can be easily followed by ultraviolet/visible
(UV/Vis) spectroscopy. Therefore, the stability of
decameric species in DMEM was analysed by UV/Vis,
at 33°C, using a 250 μM decavanadate solution (total
vanadium concentration, meaning 25 μM decameric
vanadate species). It was observed that in DMEM,
decameric species decompose through a first-order
kinetic, with a half-life time of 150 min (not shown).
Long- and short-term exposure to meta- and decavanadate
Cytotoxicity of vanadate oligomers on VSa13 cells was
tested in confluent cultures for either 15 days using
concentrations ranging from 0 to 250 μM (chronic
toxicity) or 4 h using a concentration of 1 mM (acute
toxicity). Prolonged exposure to meta- or decavanadate
similarly affected VSa13 cell viability (Fig. 2): treat-
ments with concentrations up to 7.5 μM did not
decrease cell viability (a slight increase was even
observed after 15 days), while treatments with concen-
trations from 10 to 250 μM seriously affected cell
viability, killing most of the cells at highest concen-
trations. On the contrary, short-term exposure to meta-
and decavanadate differentially affected VSa13 cell
viability (Fig. 3): While 1 mM decavanadate signifi-
cantly reduced cell viability after 2 hours, 1 mM
metavanadate showed no effects. After 4 hours, both
solutions significantly (according to ANOVA analysis)
reduced the cell viability to levels approximate to 50%.
This observation suggests that decameric vanadate
species, still present in culture medium after 2 h, are
likely to induce more toxicity effects than monomeric
vanadate species, certainly the most abundant vanadate
form found in culture medium after 4 h (half-life time
of decavanadate in DMEM was estimated at 2.5 h)
upon decameric vanadate disintegration.
Stimulation of cell proliferation by vanadate
Vanadate effect on VSa13 cell proliferation rate was
also investigated in dividing cultures (Fig. 4), and
both metavanadate and decavanadate exhibited simi-
lar effects (thus, only metavanadate results are
shown), i.e. a significant stimulation of proliferation
rate was observed for 7.5 μM concentration (accord-
Fig. 1 105.2 MHz 51V NMR spectra, at 22°C, of two vanadate
concentrations (total vanadate), namely, 1 and 5 mM of
decavanadate and metavanadate in DMEM, pH 7.1. (a) V1
and V2 signals correspond to monomeric (H2VO

4 ) and dimeric
(HV2O
3
7 and H2V2O
2
7 ) vanadate species, respectively,
irrespective of the protonation state, whereas V4 and V5
correspond to cyclic tetrameric (V4O
4
12 ) and pentameric
(V5O
5
15 ) vanadate species. V10A, V10B and V10C signals
correspond, respectively, to the V(2), V(1) and V(3) vanadium
atoms in the decameric vanadate specie (V10O
6
28 ). The
concentrations of each vanadium (V) species for metavanadate
(b) and decavanadate (c) solutions were calculated from the
fractions of the total integrated areas observed in the spectra.
For quantitative measurements, spectral parameters were kept
constant and the spectra were normalized regarding 5 mM
decavanadate spectra
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ing to ANOVA analysis). On the contrary, 10 nM
insulin (concentration used in mammalian bone-
derived cell line, Quarto et al. 1992), had no effect
on cell proliferation (Fig. 4) suggesting that vanadate,
despite proven insulin-mimetic properties, stimulates
cell proliferation. Nevertheless, no effects were
observed in cell proliferation using insulin concen-
trations up to 100 nM (not shown).
Metavanadate and decavanadate exhibit different rates
of accumulation in cells
The amount of vanadium accumulated within VSa13
cells was determined in confluent cultures treated
with 10 μM meta- or decavanadate for 0, 1, 2, 4,
8 and 24 h after subtraction of vanadium content
measured in non-treated cells (2.54±0.43 μg V/g of
protein) (Fig. 5). After 1 h of treatment, vanadium
accumulation was higher in cells treated with meta-
vanadate (4.61±0.29 μg V/g of protein) than in cells
treated with decavanadate (3.24±0.24 μg V/g of
protein), being the effect statistically significant
(according to Student’s t test). A similar, but more
pronounced, difference between meta- and decavana-
date-related vanadium accumulations was observed
after 2 h of treatment (6.85±0.4 μg and 3.95±0.1 μg
V/g of protein, respectively). Longer incubation times
resulted in a higher accumulation of vanadium
(approximately 18-fold increase above control value
after 24 h), but no significant differences were
observed between metavanadate and decavanadate
treated cells, as expected. These results suggest that
monomeric species enter VSa13 cells and accumulate
more easily than decameric species and that accumu-
lation rates become similar only when most of
decameric molecules are decomposed (half-life time
of decavanadate in DMEM was estimated at 2.5 h).
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Fig. 2 Long-term effect of metavanadate and decavanadate on
VSa13 cell viability. VSa13 cells were seeded in 96-well plates,
grown in DMEM until confluence then treated with metavana-
date (a) and decavanadate (b) using concentrations ranging
from 5 to 250 μM. Cell viability was evaluated at appropriate
times using MTS assay and is presented as the percentage of
control value (set to 100%). Values are the mean of at least
three independent experiments
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Fig. 3 Short-term effect of metavanadate and decavanadate on
VSa13 cell viability. VSa13 cells were seeded in 96-microwell
plates, grown in DMEM until confluence then treated with
1 mM metavanadate and decavanadate. Cell viability was
evaluated at appropriate times using MTS assay and is
presented as the percentage of control value (set to 100%).
Values are the mean of at least three independent experiments.
Asterisk indicates that values are statistically different in
comparison to the respective control (P<0.05 one-way
ANOVA). Dashed line indicates the half-life of decavanadate
in DMEM estimated at 2.5 h
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Vanadate and insulin decrease ECM mineralization
Vsa13 cells were cultured under mineralizing con-
ditions for 4 weeks. Then, extracellular matrix
mineralization was evaluated by densitometric analy-
sis of von Kossa staining. The effects of vanadate
(5 μM) and insulin (10 nM) on ECM mineralization
were tested separately or in combination (Fig. 6).
Vanadate 7.5 μM concentration was excluded from
this experiment because of cytotoxic effects observed
after 4 weeks of treatment (data not shown). Insulin,
metavanadate and decavanadate significantly de-
creased ECM mineralization (according to ANOVA
analysis), although to different extents: 31%, 74% and
78% decrease for insulin, meta- and decavanadate,
respectively. The combination of insulin with any of
the vanadate oligomers resulted in a more pronounced
decrease (88% and 86%, respectively), although not
significant (according to ANOVA analysis), suggest-
ing an additive effect. A lower concentration of
vanadate (2.5 μM) was also tested and shown to
exhibit a similar, but less pronounced, decrease (data
not shown) indicating a dose-dependent inhibition of
ECM mineralization by vanadate oligomers.
Discussion
The effects of vanadium on bone biology have been
extensively studied in several mammalian in vivo and
in vitro systems (Etcheverry and Cortizo 1998;
Shechter 1990), but, to our knowledge, no studies
have been performed using bone-derived systems of
aquatic vertebrate origin. In this study, we analyse, for
the first time, the effects different vanadate oligomers
have on bone-derived cell line mineralization. How-
ever, the composition of vanadate solutions is very
sensitive to vanadate concentration, pH, buffer and
other compounds used in biochemical studies. There-
fore, it is of primary importance to precisely charac-
terise the species that can interact with a system
before attempting to understand the effects promoted
by vanadate solutions. Unlike metavanadate contain-
ing several oxovanadates, decavanadate solutions
contain decameric vanadate species (V10). However,
V10 is unstable and decomposes into monomeric
vanadate with a half-life time of above 2 h in DMEM.
In this regard, effects of decavanadate were always
compared with those of metavanadate.
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Fig. 4 Effect of metavanadate and insulin on VSa13 cell
proliferation. VSa13 cells were seeded in 96-well plates at 1.5×
103 cell/well then treated with metavanadate using concen-
trations ranging from 2.5 to 7.5 μM or 10 nM insulin. Cell
proliferation was evaluated at appropriate times using MTS
assay. Values are the mean of at least three independent
experiments. Asterisk indicates that values are statistically
different in comparison to the respective control (P<0.05 one-
way ANOVA)
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Fig. 5 Vanadium accumulation in VSa13 cells upon vanadate
solutions exposure. VSa13 cells were seeded in 100-mm plates,
grown in DMEM until confluence then treated with 10 μM
metavanadate or decavanadate. At appropriate times, vanadium
content was determined by atomic absorption from cellular
extract and normalized with protein content. Vanadium content
measured in non-treated samples (2.54±0.43 μg V/g of protein)
was subtracted from each value. Asterisks indicate statistically
significant differences between metavanadate and decavanadate
according to Student’s test (**p<0.005 and ***p<0.001).
Values are the mean of at least three independent experiments.
Dashed line indicates the half-life of decavanadate in DMEM
estimated at 2.5 h
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Monomeric and decameric vanadate species affect
VSa13 cells differently
Prolonged exposure to low levels of meta- and
decavanadate similarly affected VSa13 cell viability
and proliferation, whereas short-term exposure to high
levels of decavanadate was more toxic than that of
metavanadate. In DMEM, decavanadate decomposes
into monomeric species with a half-life time of
∼150 min, suggesting that its long-term effects are
most probably caused by newly formed monomeric
species (as for metavanadate), whereas short-term
effects are likely caused by decameric vanadate
species. Considering that decavanadate solution con-
tains 10 times less molecules (particularly in shorter
exposure times, in which decameric species are
predominant) than metavanadate (in which monomer-
ic species are predominant), short-term toxicity of
decavanadate is even more remarkable. This result is
consistent with previous observations that decavana-
date and metavanadate produce different oxidative
stress levels in cardiac muscle in toadfish and gilthead
seabream (Aureliano et al. 2002; Soares et al. 2007)
and interact differently in vitro with specific proteins
such as myosin and sarcoplasmic reticulum Ca2+-
ATPase (Aureliano and Madeira 1994; Tiago et al.
2004; Aureliano and Gândara 2005). Prolonged
exposure to low levels of vanadate resulted in an
apparent increase in cell viability/number, an effect
that was previously observed in mammalian bone-
derived cell cultures (MC3T3E1 and UMR106)
(Barrio et al. 1997; Cortizo et al. 2000; Etcheverry
et al. 1997; Salice et al. 1999) and attributed to its
ability to increase phosphotyrosine protein levels and
to inhibit phosphotyrosine phosphatases, thus regu-
lating growth signalling pathways.
Although cellular accumulation of metavanadate has
been previously demonstrated in mammalian systems,
e.g. bovine kidney andCaco-2 cells (Bracken et al. 1985;
Yang et al. 2004), this process has never been analysed
in a comparative study with decavanadate. We present
evidences that vanadium differently accumulates in
VSa13 cells treated with metavanadate or decavanadate
solutions (decavanadate treatments resulted in signifi-
cantly lower vanadium accumulation at 1 and 2 h;
Fig. 5), which was probably caused by an inexistent or
a less efficient uptake mechanism for decameric species.
Vanadate stimulates VSa13 cell proliferation
Both vanadate oligomers exhibited a similar effect on
VSa13 growth rate, i.e. a stimulation of cell prolifer-
ation. A similar effect has been reported in mamma-
lian bone-derived cell lines and associated with the
activation of the insulin receptor. Insulin was shown
not to affect VSa13 cell proliferation, indicating that
either insulin receptor/signalling pathway is absent in
VSa13 cells (this hypothesis was later ruled out after
insulin was shown to affect ECM mineralization) or
vanadate stimulating effect is not mediated through
insulin signalling pathway. Several studies have
already proposed cytosolic tyrosine kinase receptor as
a mediator of vanadate proliferative effect (Shisheva
and Shechter 1992, 1993), and we propose that a
similar mechanism could occur in VSa13 cells.
Inhibition of ECM mineralization by vanadate
Mineralization of VSa13 extracellular matrix was
mildly reduced by insulin, strongly inhibited by
vanadate, regardless of its oligomerization (monomer-
ic or decameric), and even more strongly inhibited
Fig. 6 Effect of metavanadate, decavanadate and insulin on
extracellular matrix mineralization. VSa13 cells were seeded in
24-well plates, grown in DMEM until confluence then treated
for mineralization. Mineralizing cultures were subsequently
treated with 10 nM insulin (Ins), 5 μM metavanadate (MV),
5 μM decavanadate (DV), metavanadate and insulin (Ins+MV),
decavanadate and insulin (Ins+DV) or left untreated. Mineral
deposition was revealed by von Kossa staining and evaluated
by densitometric analysis. Pictures of von Kossa-stained VSa13
cells are presented above each treatment. Values are the mean
of at least three independent experiments. Asterisk indicates that
values are statistically different in comparison to the respective
control (P<0.05 one-way ANOVA)
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when both insulin and vanadate were present. Two
important regulatory effects have been associated with
vanadium osteogenic action in mammalian bone-
derived cells: the inhibition of alkaline phosphatase
activity and the stimulation of type I collagen
synthesis (Barrio and Etcheverry 2006; Canalis
1985b; Lau et al. 1988). Both processes are essential
to the correct mineralization of the extracellular
matrix of bone cells (Murshed et al. 2005), and it is
likely that vanadium effect on vertebrate bone
depends on the equilibrium between its stimulatory
and inhibitory properties. Vanadium derivatives were
previously shown to specifically activate insulin-
associated pathways (i.e. MAPK and PI-3K pathways)
through phosphorylation of common intermediates
such as extracellular signal-regulated kinase (ERK)
(Barrio and Etcheverry 2006). Moreover, vanadium
proliferative effect was reverted by specific inhibitors
of insulin-associated pathways. In one of those
studies, vanadyl (IV)-ascorbate, a vanadium complex,
significantly increased the rate and extent of mineral
deposition within the ECM of mouse MC3T3-E1
bone-derived cells and stimulated type I collagen
synthesis (Cortizo et al. 2006). These effects were
apparently related to both MAPK and PI-3K path-
ways activation and ERK increased phosphorylation.
In another study, it was described that the alkaline
phosphatase activity is inhibited in MC3T3-E1 cells
by a trehalose vanadyl complex independently of
regular insulin-associated pathways. Based on pub-
lished results, we suggest that vanadate inhibitory
effect on VSa13 ECM mineralization could be
associated with either direct interference of vanadium
into key processes such as alkaline phosphatase
activity, or indirect interference of vanadium into
insulin-associated pathways. Recently, it was shown
that the ECM mineralization of MC3T3-E1 cells is
inhibited by platelet-derived growth factor through
ERK activation (Kono et al. 2007). This result is, on
one hand, contradictory to a previous observation
where ECM mineralization of MC3T3-E1 cells was
stimulated by vanadium through ERK activation
(Cortizo et al. 2006), but, on the other hand, in total
agreement with the inhibition of VSa13 ECM
mineralization by vanadate, possibly through ERK
activation. The characterisation of the mechanisms
involved in vanadate inhibitory effect in VSa13 cell
line will need to be investigated in future studies.
Conclusion
Vanadate was shown here to accumulate within
VSa13 bone-derived cells, stimulating growth perfor-
mance through insulin-independent mechanisms and
preventing ECM mineralization probably through
multiple processes involving regulation that may or
may not depend on the activation of insulin-stimulated
pathways. The presence of decameric vanadate species
was also shown to produce differences (accumulation
and cytotoxicity) between meta- and decavanadate in
short-term exposure while acting similarly in pro-
longed exposure caused eventually by the decomposi-
tion of decavanadate into other oligomers. VSa13 cells
were shown to be a suitable model to study vanadium
mechanisms of action in vertebrate bone development
and to be a good alternative to mammalian systems.
Acknowledgements The authors thank Dr. Hélio Martins
from the Faculty of Sciences and Technology (FCT) of the
University of Algarve for his technical help in the course of
atomic absorption spectrometry experiments. Thanks also to
J.J.G. Moura, REQUIMTE, New University of Lisbon, for
the esteemed collaboration in the NMR studies. DMT was the
recipient of a Ph.D. fellowship (BD/12773/2003) from the
Portuguese Science and Technology Foundation.
References
Amado AM, Aureliano M, Ribeiro-Claro PJA, Teixeira-Dias JJ.
Combined Raman and V-51 NMR spectroscopic study
of vanadium (V) oligomerization in aqueous alkaline-
solutions. J Raman Spectrosc 1993;24:699–703.
Anke M. Vanadium – An element both essential and toxic to
plants, animals and humans? Anal Real Acad Nac Farm
2004;70:961–99.
Aureliano M, Madeira VM. Interactions of vanadate oligomers
with sarcoplasmic reticulum Ca(2+)-ATPase. Biochim
Biophys Acta 1994;1221:259–71.
Aureliano M, Gandara RM. Decavanadate effects in biological
systems. J Inorg Biochem 2005;99:979–85.
Aureliano M, Joaquim N, Sousa A, Martins H, Coucelo JM.
Oxidative stress in toadfish (Halobactrachus didactylus)
cardiac muscle. Acute exposure to vanadate oligomers. J
Inorg Biochem 2002;90:159–65.
Barrio DA, Etcheverry SB. Vanadium and bone development:
putative signaling pathways. Can J Physiol Pharmacol
2006;84:677–86.
Barrio DA, Braziunas MD, Etcheverry SB, Cortizo AM. Maltol
complexes of vanadium (IV) and (V) regulate in vitro
alkaline phosphatase activity and osteoblast-like cell
growth. J Trace Elem Med Biol 1997;11:110–5.
Cell Biol Toxicol (2008) 24:253–263 261
Bracken WM, Sharma RP, Elsner YY. Vanadium accumulation
and subcellular distribution in relation to vanadate induced
cytotoxicity in vitro. Cell Biol Toxicol 1985;1:259–68.
Canalis E. Effect of sodium vanadate on deoxyribonucleic acid
and protein synthesis in culture rat calvariae. Endocrinology
1985a;116:855–62.
Canalis E. Effect of sodium vanadate on deoxyribonucleic acid and
protein syntheses in cultured rat calvariae. Endocrinology
1985b;116:855–62.
Cheatham B, Kahn CR. Insulin action and the insulin signaling
network. Endocr Rev 1995;16:117–42.
Cohick WS, Clemmons DR. The insulin-like growth factors.
Annu Rev Physiol 1993;55:131–53.
Cortizo AM, Etcheverry SB. Vanadium derivatives act as
growth factor-mimetic compounds upon differentiation
and proliferation of osteoblast-like UMR106 cells. Mol
Cell Biochem 1995;145:97–102.
Cortizo AM, Bruzzone L, Molinuevo S, Etcheverry SB. A
possible role of oxidative stress in the vanadium-induced
cytotoxicity in the MC3T3E1 osteoblast and UMR106
osteosarcoma cell lines. Toxicology 2000;147:89–99.
Cortizo AM, Molinuevo MS, Barrio DA, Bruzzone L.
Osteogenic activity of vanadyl(IV)-ascorbate complex:
evaluation of its mechanism of action. Int J Biochem Cell
Biol 2006;38:1171–80.
Crans DC, Smee JJ, Gaidamauskas E, Yang L. The chemistry and
biochemistry of vanadium and the biological activities exerted
by vanadium compounds. Chem Rev 2004;104:849–902.
Dubyak GR, Kleinzeller A. The insulin-mimetic effects of
vanadate in isolated rat adipocytes. Dissociation from
effects of vanadate as a (Na+-K+) ATPase inhibitor. J Biol
Chem 1980;255:5306–12.
Etcheverry SB, Cortizo AM. Bioactivity of vanadium com-
pounds on cells in culture. In: Nriagu JO, editor. Vanadium
in the environment. New York: John Wiley & Sons; 1998.
Etcheverry SB, Apella MC, Baran EJ. A model study of the
incorporation of vanadium in bone. J Inorg Biochem
1984;20:269–74.
Etcheverry SB, Crans DC, Keramidas AD, Cortizo AM. Insulin-
mimetic action of vanadium compounds on osteoblast-like
cells in culture. Arch Biochem Biophys 1997;338:7–14.
Goldwaser I, Gefel D, Gershonov E, Fridkin M, Shechter Y.
Insulin-like effects of vanadium: basic and clinical
implications. J Inorg Biochem 2000;80:21–5.
Heyliger CE, Tahiliani AG, McNeill JH. Effect of vanadate on
elevated blood glucose and depressed cardiac performance
of diabetic rats. Science 1985;227:1474–7.
Kato Y, Iwamoto M, Koike T, Suzuki F. Effect of vanadate on
cartilagematrix proteoglycan synthesis in rabbit costal
chondrocyte cultures. J Cell Biol 1987;104:311–9.
Kono SJ, OshimaY, Hoshi K, Bonewald LF, Oda H, Nakamura K,
et al. Erk pathways negatively regulate matrix mineralization.
Bone 2007;40:68–74.
Lau KH, Tanimoto H, Baylink DJ. Vanadate stimulates bone
cell proliferation and bone collagen synthesis in vitro.
Endocrinology 1988;123:2858–67.
LeRoith D. Insulin-like growth factor I receptor signaling-
overlapping or redundant pathways? Endocrinology 2000;
141:1287–8.
Malich G, Markovic B, Winder C. The sensitivity and
specificity of the MTS tetrazolium assay for detecting the
in vitro cytotoxicity of 20 chemicals using human cell
lines. Toxicology 1997;124:179–92.
McCarthy TL, Ji C, Centrella M. Links among growth factors,
hormones, and nuclear factors with essential roles in bone
formation. Crit Rev Oral Biol Med 2000;11:409–22.
Meyerovitch J, Farfel Z, Sack J, Shechter Y. Oral administra-
tion of vanadate normalizes blood glucose levels in
streptozotocin-treated rats. Characterization and mode of
action. J Biol Chem 1987;262:6658–62.
Moriyama S, Ayson FG, Kawauchi H. Growth regulation by
insulin-like growth factor-I in fish. Biosci Biotechnol
Biochem 2000;64:1553–62.
Murshed M, Harmey D, Millan JL, McKee MD, Karsenty G.
Unique coexpression in osteoblasts of broadly expressed
genes accounts for the spatial restriction of ECM miner-
alization to bone. Genes Dev 2005;19:1093–104.
Nielsen FH, Uthus EO. The essentiality and metabolism of
vanadium. In: Chasteen ND, editor. Vanadium in biolog-
ical systems. Boston: Kluwer Academic Publishers; 1990.
Pombinho AR, Laize V, Molha DM, Marques SM, Cancela
ML. Development of two bone-derived cell lines from the
marine teleost Sparus aurata; evidence for extracellular
matrix mineralization and cell-type-specific expression of
matrix Gla protein and osteocalcin. Cell Tissue Res
2004;315:393–406.
Quarto R, Campanile G, Cancedda R, Dozin B. Thyroid
hormone, insulin and glucocorticoids are sufficient to
support chondrocyte differentiation to hypertrophy: a
serum-free analysis. J Cell Biol 1992;119:989–95.
Rehder D. The coordination chemistry of vanadium as related
to its biological functions. Coord Chem Rev
1999;182:297–322.
Rehder D. Biological and medicinal aspects of vanadium. Inorg
Chem Commun 2003;6:604–17.
Salice VC, Cortizo AM, Gomez Dumm CL, Etcheverry SB.
Tyrosine phosphorylation and morphological transforma-
tion induced by four vanadium compounds on MC3T3E1
cells. Mol Cell Biochem 1999;198:119–28.
Shechter Y. Perspective in diabetes: insulin-mimetic effects of
vanadate. Possible implications for future treatment of
diabetes. Diabetes 1990;39:1–5.
Shechter Y, Karlish SJ. Insulin-like stimulation of glucose
oxidation in rat adipocytes by vanadyl (IV) ions. Nature
1980;284:556–8.
Shechter Y, Li J, Meyerovitch J, Gefel D, Bruck R, Elberg G, et
al. Insulin-like actions of vanadate are mediated in an
insulin-receptor-independent manner via non-receptor pro-
tein tyrosine kinases and protein phosphotyrosine phos-
phatases. Mol Cell Biochem 1995;153:39–47.
Shisheva A, Shechter Y. A cytosolic protein tyrosine kinase in
rat adipocytes. FEBS Lett 1992;300:93–6.
262 Cell Biol Toxicol (2008) 24:253–263
Shisheva A, Shechter Y. Role of cytosolic tyrosine kinase in
mediating insulin-like actions of vanadate in rat adipo-
cytes. J Biol Chem 1993;268:6463–9.
Soares SS, Martins H, Aureliano M. Vanadium distribution
following decavanadate administration. Arch Environ
Contam Toxicol 2006;50:60–4.
Soares SS, Martins H, Duarte RO, Moura JJG, Coucelo J,
Gutiérrez-Merino C, et al. Vanadium distribution, lipid
peroxidation and oxidative stress markers upon decava-
nadate in vivo administration. J Inorg Biochem 2007;
101:80–8.
Tiago T, Aureliano M, Gutierrez-Merino C. Decavanadate
binding to a high affinity site near the myosin catalytic
centre inhibits F-actin-stimulated myosin ATPase activity.
Biochemistry 2004;43:5551–61.
Yang XG, Yang XD, Yuan L, Wang K, Crans DC. The
permeability and cytotoxicity of insulin-mimetic vanadium
compounds. Pharm Res 2004;21:1026–33.
Cell Biol Toxicol (2008) 24:253–263 263
